商品编号


F1410



品牌


UBPBio



公司


Ubiquitin-Proteasome Biotechnologies, LLC



公司分类


Inhibitors



Size

5 mg

商品信息

ONX-0914, also known as PR-957, is a potent inhibitor of the immunoproteasome with minimal cross-reactivity for the constitutive proteasome. ONX-0914 selectively inhibits low-molecular mass polypeptide-7 (LMP7), the subunit specific for the immunoproteasome that catalyzes the chymotyrpsion-like activity, with an IC
50
< 100="" nm.="" cell="" culture="" and="" animal="" studies="" have="" shown="" that="" onx-0914="" blocks="" the="" production="" of="" proinflammatory="" cytokines="" including="" interleukin-6="" and="" 17,="" indicating="" that="" it="" has="" potential="" uses="" in="" the="" treatment="" of="" some="" autoimmune="" diseases="" such="" as="" rheumatoid="" arthritis,="" inflammatory="" bowel="" disease="" and="" lupus.="">

Dose: 0.1-0.5 μM for in vitro or cell couture assays; intravenous or subcutaneous admi
NIST
ration at 2-10 mg/Kg daily for 5-7 days for animal studies.

Additional Information






Product Name:

ONX-0914 (PR-957)



Also Known As:

ONX 0914; ONX0914; ONX-0914; PR-957; CAS#: 960374-59-8



Catalog No.:

F1410



Size:

5 mg



Molecular Weight:

580.7 Da



Species:

N/A



Source:

Synthetic



Stock:

Powder



Concentration:

N/A



Quality Assurance:

>98% by HPLC and NMR



Storage:

Elig
IBL
e for room temperature shipping. Store at -80°C upon receiving; avoid multiple freeze-thaw cycles after dissolving in DMSO.



PDF Data Sheet:

PDF Datasheet



NCBI RefSeq:

N/A



Image(s):

No



Shipping Method:

Room temperature shipping



References:

1. Muchamuel T,
et al
. (2009) Nat Med. 15(7):781-7.
2. Basler M,
et al
. (2010) J Immunol. 185(1):634-41. 3. Kalim KW,
et al
. (2012) J Immunol. 189(8):4182-93.




Details

ONX-0914, also known as PR-957, is a potent inhibitor of the immunoproteasome with minimal cross-reactivity for the constitutive proteasome. ONX-0914 selectively inhibits low-molecular mass polypeptide-7 (LMP7), the subunit specific for the immunoproteasome that catalyzes the chymotyrpsion-like activity, with an IC
50
< 100="" nm.="" cell="" culture="" and="" animal="" studies="" have="" shown="" that="" onx-0914="" blocks="" the="" production="" of="" proinflammatory="" cytokines="" including="" interleukin-6="" and="" 17,="" indicating="" that="" it="" has="" potential="" uses="" in="" the="" treatment="" of="" some="" autoimmune="" diseases="" such="" as="" rheumatoid="" arthritis,="" inflammatory="" bowel="" disease="" and="" lupus.="">
Dose: 0.1-0.5 μM for in vitro or cell couture assays; intravenous or subcutaneous admi
NIST
ration at 2-10 mg/Kg daily for 5-7 days for animal studies.